No Data
No Data
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
The world's first non-COVID mRNA vaccine approved! The market has a blue ocean, can the new RSV leader make a comeback?
① The hundred-billion-dollar RSV vaccine market has seen the entry of "new nobility", as well as the world's first non-COVID mRNA vaccine approved. ② Analysis suggests that whether it is a recombinant protein vaccine or an mRNA vaccine, which technological route can better meet clinical needs in the future will be a key evaluation factor. ③ The advantage of mRNA vaccines lies in their low cost and rapid development and production.
Express News | US Centers for Disease Control and Prevention: In the week ending February 4, the Omicron strain subtype XBB.1.5 accounted for 66.4% of the total number of COVID-19 cases in the US.
No Data
No Data